
	SignalChem Lifesciences Corporation is a privately owned biopharmaceutical company specializing in the discovery and development of kinase inhibitors as innovative therapies for cancer, inflammation and neurological diseases.

	&nbsp;

	The Company has a robust kinase platform encompassing 450 kinase targets and assays for the development and commercialization of unique therapies in many diseases.

	&nbsp;

	This vast resource empowers SLC&rsquo;s scientists to identify novel drug candidates against kinase targets of interest.

	&nbsp;

	Another key part of SLC&rsquo;s kinase drug development platform is KineCore, a kinase focused small molecule library that was designed and assembled in-house.
